We have located links that may give you full text access.
Can ICER bring cost-effectiveness to drug prices?
Managed Care 2019 June
Insurers and some drug manufacturers are turning to the Institute for Clinical and Economic Review (ICER) as the arbiter of drug prices, especially as prices soar and value is sought. But questions persist about the cost-effectiveness calculations of the Boston not-for-profit and its dependence on QALYs.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app